Residency · Residency · Obstetrics Gynecology
Ectopic Pregnancy: Diagnosis and Management
Overview
Ectopic pregnancy is the implantation of a fertilized ovum outside the endometrial cavity. It occurs in 1 to 2% of all pregnancies and accounts for 2.7% of pregnancy-related deaths, making it the leading cause of first-trimester maternal mortality. The vast majority (95%) are tubal, with the ampullary segment being the most common location (70%), followed by the isthmic segment (12%), fimbrial segment (11%), and interstitial or cornual segment (2%). Non-tubal ectopics account for the remaining 5% and include ovarian, cervical, cesarean scar, abdominal, and heterotopic pregnancies.
Risk Factors
The strongest risk factor is a prior ectopic pregnancy, which carries a 10 to 25% recurrence risk. A history of pelvic inflammatory disease or sexually transmitted infection, with Chlamydia trachomatis being the most significant organism, increases risk substantially. Prior tubal surgery, including tubal ligation, salpingectomy, and tubal reanastomosis, is a major risk factor. Current IUD use does not increase the absolute risk of ectopic pregnancy, but if pregnancy occurs with an IUD in place, a higher proportion of those pregnancies are ectopic. Endometriosis, in utero DES exposure, cigarette smoking (which impairs tubal motility), assisted reproductive technology (with a 2 to 5% ectopic rate with IVF), increasing age, and prior pelvic or abdominal surgery all contribute to risk.
Clinical Presentation
The classic triad of amenorrhea, vaginal bleeding, and unilateral pelvic or abdominal pain is present in only about 50% of cases. A ruptured ectopic may present with hemodynamic instability including tachycardia, hypotension, and peritoneal signs. Shoulder pain from referred irritation of the diaphragm by hemoperitoneum is a worrisome finding. On exam, cervical motion tenderness and adnexal mass or tenderness may be present. Some patients are asymptomatic, with the ectopic discovered on early ultrasound.
Diagnosis
Beta-hCG
A quantitative serum beta-hCG is essential. The discriminatory level is the hCG value above which a normal intrauterine pregnancy should be visible on transvaginal ultrasound, typically 1,500 to 2,000 mIU/mL, though some centers use 3,000 to 3,500 to avoid misdiagnosing a very early viable intrauterine pregnancy. In normal early viable pregnancies, hCG should rise by at least 53% over 48 hours, based on revised Barnhart data (previously 66%). A slower-than-expected rise is concerning for ectopic or failing intrauterine pregnancy. A plateau suggests ectopic or failing pregnancy. A decline slower than expected for spontaneous miscarriage raises concern for ectopic.
Transvaginal Ultrasound
Findings suggestive of ectopic pregnancy include an empty uterus with beta-hCG above the discriminatory level, an extraovarian adnexal mass (the most specific finding), the "tubal ring sign" or "blob sign" (an echogenic ring in the adnexa separate from the ovary), free fluid in the cul-de-sac (echogenic fluid suggests hemoperitoneum), and rarely cardiac activity outside the uterus (which is a definitive diagnosis). A pseudogestational sac is a small collection of fluid within the endometrial cavity representing a decidual reaction; it lacks the double decidual sign or yolk sac of a true intrauterine pregnancy.
<image>Transvaginal ultrasound images showing ectopic pregnancy findings: an empty uterus with pseudogestational sac, an adnexal mass separate from the ovary with the tubal ring sign, free fluid in the posterior cul-de-sac, and a live ectopic pregnancy with fetal pole and cardiac activity in the adnexa</image>
Pregnancy of Unknown Location (PUL)
When hCG is positive but no intrauterine pregnancy or ectopic is seen on ultrasound, and the hCG is below or near the discriminatory level, the situation is classified as a pregnancy of unknown location. This is a common scenario in early pregnancy. Management involves serial hCG measurements every 48 hours and repeat transvaginal ultrasound. Close follow-up is required until the location of the pregnancy is established.
Management Options
Expectant Management
Expectant management may be considered when hCG is low and declining, consistent with spontaneous resolution. Requirements include reliable follow-up, hemodynamic stability, and no evidence of rupture. Serial hCG monitoring continues until levels are undetectable. This approach is possible in select cases with very low and declining hCG.
Medical Management: Methotrexate
Eligibility Criteria
Methotrexate can be used when the patient is hemodynamically stable, there are no signs of rupture, the patient can comply with follow-up, and liver and renal function are normal. There should be no active hepatic or pulmonary disease, no immunodeficiency, and no breastfeeding. Laboratory requirements include a WBC above 1,500 and platelets above 100,000.
Relative Contraindications
Factors that reduce the success rate of methotrexate include fetal cardiac activity on ultrasound, hCG above 5,000 mIU/mL (some centers use 5,000 to 10,000 as a cutoff), an ectopic mass larger than 4 cm, and significant free fluid suggesting possible rupture.
Single-Dose Protocol (Most Common)
Methotrexate is given at 50 mg/m2 intramuscularly as a single dose. HCG is checked on day 4 and day 7. If the decline between day 4 and day 7 is at least 15%, weekly hCG monitoring continues until levels are undetectable. If the decline is less than 15%, a second dose of 50 mg/m2 is administered. Up to two additional doses may be given, for a total of three doses within the "single-dose" protocol. The success rate is 85 to 90% with a single dose, with higher rates in early, low-hCG ectopics.
Two-Dose Protocol
Methotrexate at 50 mg/m2 is given on day 1 and day 4. HCG is checked on day 4 and day 7. If the decline is at least 15% between day 4 and 7, weekly monitoring follows. If the decline is less than 15%, additional doses are given on day 7 and day 11. This protocol has a higher success rate than the true single-dose approach, at approximately 93%.
| MTX Protocol | Dosing | hCG Monitoring | Success Rate |
|---|---|---|---|
| Single-dose | 50 mg/m² IM day 1 | Days 4 and 7; repeat if <15% decline | 85-90% |
| Two-dose | 50 mg/m² IM days 1 and 4 | Days 4 and 7; additional doses days 7, 11 if needed | ~93% |
| Multi-dose (fixed) | 1 mg/kg IM days 1, 3, 5, 7 + folinic acid | Until ≥15% decline between consecutive values | ~93% |
Multi-Dose (Fixed) Protocol
Methotrexate at 1 mg/kg intramuscularly is given on days 1, 3, 5, and 7, alternating with folinic acid at 0.1 mg/kg on days 2, 4, 6, and 8. Treatment continues until hCG declines by at least 15% between consecutive measurements. This protocol has a success rate of approximately 93% but causes more side effects. It is reserved for higher hCG levels, larger ectopics, or cases with fetal cardiac activity.
Patient Instructions During MTX Treatment
Patients should avoid folic acid-containing prenatal vitamins, NSAIDs (which impair methotrexate clearance), sun exposure (due to photosensitivity), alcohol, sexual intercourse, and vigorous exercise. They should report to the emergency department for severe abdominal pain, dizziness, fainting, or heavy vaginal bleeding. A transient hCG rise between days 1 and 4 is expected and should not prompt re-treatment. "Separation pain," mild abdominal discomfort occurring between days 3 and 7, affects 50 to 75% of patients and does not indicate rupture.
<image>Methotrexate treatment protocols for ectopic pregnancy: single-dose protocol timeline showing MTX injection on day 1, hCG measurements on days 4 and 7 with decision points for repeat dosing, and two-dose protocol with injections on days 1 and 4, with hCG monitoring schedule and criteria for successful response versus need for additional doses</image>
Surgical Management
Indications
Surgery is indicated for ruptured ectopic or hemodynamic instability, contraindications to methotrexate, failed medical management, heterotopic pregnancy (where an intrauterine pregnancy coexists with an ectopic), and patient preference.
Salpingectomy vs. Salpingostomy
Salpingectomy (removal of the tube) is preferred in most cases and is the standard of care when the contralateral tube is normal. It eliminates the risk of persistent ectopic tissue and removes the need for hCG follow-up to detect persistent trophoblast. The ESEP and DEMETER trials demonstrated that salpingectomy does not reduce future fertility compared with salpingostomy when the other tube is healthy. Salpingostomy (tube-sparing surgery) is considered when the contralateral tube is absent or damaged or when the patient strongly desires tubal preservation. It requires follow-up hCG until undetectable because of a 7% persistent ectopic rate. Laparoscopy is preferred over laparotomy because of less morbidity and faster recovery. Laparotomy is reserved for hemodynamic instability or when laparoscopy is not available or feasible.
Special Situations
Interstitial (Cornual) Ectopic
An interstitial ectopic is implanted in the interstitial portion of the tube within the myometrium. It can grow larger before rupture because of the surrounding myometrial tissue. Rupture can be catastrophic due to the proximity of the uterine artery. Ultrasound shows an eccentrically located gestational sac with a thin myometrial mantle of less than 5 mm. Unruptured cases can be treated with methotrexate. Surgical management involves cornual wedge resection or cornuostomy.
Cesarean Scar Ectopic
The incidence of cesarean scar ectopic is increasing with rising cesarean rates. Ultrasound shows a gestational sac embedded in the anterior lower uterine segment scar with thin or absent myometrium between the sac and the bladder. There is high risk of hemorrhage, uterine rupture, and placenta accreta spectrum if the pregnancy continues. No consensus exists on optimal management; options include methotrexate (local or systemic), uterine artery embolization, dilation and curettage with ultrasound guidance, or surgical excision.
Heterotopic Pregnancy
A heterotopic pregnancy is the coexistence of an intrauterine pregnancy and an ectopic pregnancy. The incidence is approximately 1 in 30,000 in spontaneous conception but rises to as high as 1 in 100 with IVF. Methotrexate cannot be used because it would harm the intrauterine pregnancy. Treatment is surgical removal of the ectopic while preserving the intrauterine pregnancy.
Cervical Ectopic
Cervical ectopic pregnancy is rare but carries a risk of life-threatening hemorrhage. Ultrasound shows a gestational sac within the cervical stroma below the internal os. Treatment options include methotrexate (local injection or systemic), sometimes combined with cervical cerclage or balloon tamponade. Hysterectomy is reserved for uncontrolled hemorrhage.
Clinical Pearls
Always obtain a beta-hCG before any procedure for first-trimester bleeding or pelvic pain. Do not assume a negative urine test excludes pregnancy.
An empty uterus with hCG above the discriminatory level is an ectopic until proven otherwise.
The discriminatory level is a guideline, not an absolute. Clinical judgment should prevail, as a very early viable intrauterine pregnancy may not be visible at 1,500 to 2,000 mIU/mL.
Never give methotrexate without confirmed absence of an intrauterine pregnancy. Always verify with ultrasound.
A transient rise in hCG on days 1 to 4 after methotrexate is expected and should not prompt re-dosing or surgery.
Salpingectomy is preferred over salpingostomy when the contralateral tube is healthy, offering equivalent future fertility with a lower risk of persistent trophoblast.
Heterotopic pregnancy is rare in natural conception but should always be considered in IVF patients presenting with ectopic symptoms.
Interstitial and cesarean scar ectopics carry the highest morbidity risk due to their vascularity and potential for massive hemorrhage.
References
- ACOG Practice Bulletin No. 193: Tubal Ectopic Pregnancy (2018, reaffirmed 2023)
- Barnhart KT. Clinical practice: ectopic pregnancy. N Engl J Med. 2009;361:379-387
- Mol F et al. (ESEP study). Salpingotomy versus salpingectomy in women with tubal pregnancy. Lancet. 2014;383:1483-1489
- ASRM Practice Committee. Medical treatment of ectopic pregnancy. Fertil Steril. 2013;100:638-644
- Lipscomb GH. Medical therapy for ectopic pregnancy. Semin Reprod Med. 2007;25:93-98
- Timor-Tritsch IE et al. Cesarean scar pregnancy: diagnosis and management. Ultrasound Obstet Gynecol. 2012;40:247-256
